PETACH TIKVA, Israel, March 2, 2015 (GLOBE NEWSWIRE) -- Macrocure Ltd. (Nasdaq:MCUR), a clinical-stage biopharmaceutical company focused on developing a novel therapeutic platform to address chronic and hard-to-heal wounds, today announced that Dr. Ramesh Tharuvai has joined Macrocure as Vice President, Operations effective March 2, 2015.
Most recently, Dr. Tharuvai was Vice President, Manufacturing and Product Supply, at Nuron Biotech, a private, clinical stage biopharmaceuticals company. Prior to Nuron, Dr. Tharuvai held senior-level positions at Pfizer and Wyeth within supply chain and operations. For more than 10 years, he was responsible for modeling, redesigning, and improving performance in several global product portfolios as well as establishing the Sales & Operations Planning process for Wyeth's Vaccine business and global portfolio. At Pfizer, Dr. Tharuvai had responsibility for the Specialty Care supply chain, which included 22 brands of biologics, vaccines, and small molecules.
"Dr. Tharuvai is a seasoned leader with an established track record of accomplishment in manufacturing, supply chain management and process optimization," stated Nissim Mashiach, President and Chief Executive Officer of Macrocure. "Dr. Tharuvai's experience at small and large companies, including assuring compliance with FDA and EMA requirements, will be invaluable as Macrocure expands its manufacturing footprint from clinical stage production to large scale, commercial operations. His addition is consistent with our focused strategy to round out our existing world-class management team. Dr. Tharuvai will lead the establishment of Macrocure's new manufacturing plant and will be actively involved in the preparation of our BLA submission," concluded Mr. Mashiach.
Dr. Tharuvai holds a B. Tech degree in Chemical Engineering from the Indian Institute of Technology, and an M.S. and Ph.D. from Ohio State University. Additionally, he earned a Six Sigma Black Belt Certification from Villanova University.
About Macrocure Ltd.
Founded in 2008, Macrocure Ltd. is a clinical-stage biotechnology company focused on developing a novel therapeutic platform to address chronic and hard-to-heal wounds, such as DFUs and VLUs. The Company's novel approach is to treat and close chronic and other hard-to-heal wounds by injecting the human body's own wound healing and regenerative components directly into the wound itself. For more information, please visit www.Macrocure.com.
Cautionary Note Regarding Forward-Looking Statements
This press release includes forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, Section 21E of the US Securities Exchange Act of 1934, as amended, and the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are statements that are not historical facts, such as statements regarding assumptions and results related to financial results forecasts, commercial results, clinical trials and regulatory authorizations. Forward-looking statements are based on Macrocure's current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors including, but not limited to, unexpected results of clinical trials, delays or denial in regulatory approval process or additional competition in the market. The forward-looking statements made herein speak only as of the date of this release and Macrocure undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.
CONTACT: Francesca DeMartino Investor Relations & Corporate Communications +1 (310) 739-6476 [email protected]